Totality of evidence in trials of sodium–glucose co-transporter-2 inhibitors in the patients with heart failure with reduced ejection fraction: implications for clinical practice

Review concludes that evidence from two large-scale randomized placebo-controlled trials demonstrates a favourable effect of dapagliflozin and empagliflozin on the clinical course of heart failure with or without diabetes, suggesting they are a new standard of care.


European Heart Journal